|
|
|
| Platelet activation and the protective effect of aprotinin in hepatolithiasis patients |
| Wen-Ming Feng, Ying Bao, Mao-Yun Fei, Qiu-Qiang Chen, Qi Yang and Chuang Dai |
Huzhou, China
From the Department of Hepatobiliary Surgery, First Hospital of Huzhou, Huzhou 313000, China (Feng WM, Bao Y, Fei MY, Chen QQ, Yang Q and Dai C)
Correspondence: Wen-Ming Feng, MD, Department of Hepatobiliary Surgery, First Hospital of Huzhou, Huzhou 313000, China (Tel: 86-572-2211208; Fax: 86-572-202 3728; Email: d_fwm@hotmail.com) |
|
|
|
|
Abstract OBJECTIVE: To explore platelet activation and the protective effect of aprotinin in patients with hepatolithiasis.
METHODS: The count of platelets and levels of CD62P and CD63 were measured by flow cytometry in 38 patients with hepatolithiasis. Several measurements were carried out after treatment with aprotinin.
RESULTS: The levels of CD62P, CD63 in patients with hepatolithiasis were higher than those in patients with cholecystolithiasis (P<0.05), but the count of platelets was lower (P<0.05). After operation, the levels of CD62P, CD63 were significantly increased in patients with hepatolithiasis, but the count of platelets was lower (P<0.05). Postoperative levels of CD62P, CD63 were significantly lower in patients treated with aprotinin than in normal controls (P<0.05); but there was no significant change in the count of platelets in the two groups.
CONCLUSION: Platelet activation occurs in patients with hepatolithiasis, and may be inhibited by aprotinin.
|
|
|
|
|
|
|
|
|
2003, Vol. 2 
